Latest Dermatology News

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a regulatory delay as the Foreign Investment Review Board extends its approval deadline, pushing the court hearing to mid-November.

Mayne Pharma updates shareholders on the extended Foreign Investment Review Board approval deadline and the rescheduled court hearing for its acquisition scheme by Cosette Australia BidCo.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

Zelira Therapeutics has made significant progress in its HOPE 1 clinical trial program, completing a key FDA submission and securing a $650,000 non-dilutive R&D loan facility to support ongoing development and working capital needs.

Mayne Pharma has announced the rescheduling of its Supreme Court hearing to November 3, 2025, to approve the acquisition scheme by Cosette Australia BidCo, pending Foreign Investment Review Board approval.

Botanix Pharmaceuticals reports a strong start to FY26 with a 50% surge in Sofdra prescriptions and a 65% rise in net revenue, underpinned by a larger sales team and operational efficiencies.

Mayne Pharma’s planned acquisition by Cosette Pharmaceuticals faces a delay as the Foreign Investment Review Board postpones its decision, potentially pushing back key court proceedings.

Mayne Pharma has won a key legal battle against Cosette Pharmaceuticals, clearing the way for its acquisition scheme to proceed pending final approvals. Shareholders can expect the deal to move forward with payments scheduled soon.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.